Mostrar el registro sencillo del ítem

dc.contributor.authorGalvez Fernandez, Marta
dc.contributor.authorGrau-Perez, Maria
dc.contributor.authorGarcia-Barrera, Tamara
dc.contributor.authorRamirez-Acosta, Sara
dc.contributor.authorGomez-Ariza, Jose L.
dc.contributor.authorPerez-Gomez, Beatriz
dc.contributor.authorGalan-Labaca, Iñaki
dc.contributor.authorNavas-Acien, Ana
dc.contributor.authorRedon, Josep
dc.contributor.authorBriongos Figuero, Laisa Socorro
dc.contributor.authorDueñas-Laita, Antonio
dc.contributor.authorPérez Castrillon, José Luis 
dc.contributor.authorTellez Plaza, Maria
dc.contributor.authorMartín Escudero, Juan Carlos 
dc.date.accessioned2024-01-24T12:42:14Z
dc.date.available2024-01-24T12:42:14Z
dc.date.issued2021
dc.identifier.citationFree Radical Biology and Medicine, Enero 2021, vol.162, p. 392-400.es
dc.identifier.issn0891-5849es
dc.identifier.urihttps://uvadoc.uva.es/handle/10324/64965
dc.description.abstractBackground and objectives: Experimental data suggest that trace elements, such as arsenic (As), cadmium (Cd), and selenium (Se) can influence the bone remodeling process. We evaluated the cross-sectional association betweenAs, Cd, and Se biomarkers with bone mineral density (BMD) measured at the calcaneus, in a representativesample of a general population from Spain. As secondary analyses we evaluated the associations of interest in subgroups defined by well-established BMD determinants, and also conducted prospective analysis of osteoporosis-related incident bone fractures restricted to participants older than 50 years-old. Methods: In N = 1365 Hortega Study participants >20 years-old, urine As and Cd were measured by inductively coupled-plasma mass spectrometry (ICPMS); plasma Se was measured by atomic absorption spectrometry (AAS) with graphite furnace; and BMD at the calcaneus was measured using the Peripheral Instaneuous X-ray Imaging system (PIXI). As levels were corrected for arsenobetaine (Asb) to account for inorganic As exposure. Results: The median of total urine As, Asb-corrected urine As, urine Cd, and plasma Se was 61.3, 6.53 and 0.39 μg/g creatinine, and 84.9 μg/L, respectively. In cross-sectional analysis, urine As and Cd were not associated with reduced BMD (T-score < -1 SD). We observed a non-linear dose-response of Se and reduced BMD, showing an inverse association below ~105 μg/L, which became increasingly positive above ~105 μg/L. The evaluated subgroups did not show differential associations. In prospective analysis, while we also observed a U-shape doseresponse of Se with the incidence of osteoporosis-related bone fractures, the positive association above ~105 μg/L was markedly stronger, compared to the cross-sectional analysis. Conclusions: Our results support that Se, but not As and Cd, was associated to BMD-related disease. The association of Se and BMD-related disease was non-linear, including a strong positive association with osteoporosisrelated bone fractures risk at the higher Se exposure range. Considering the substantial burden of bone loss in elderly populations, additional large prospective studies are needed to confirm the relevance of our findings to bone loss prevention in the population depending on Se exposure levels.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.publisherELSEVIERes
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.subject.classificationBone mineral density, Arsenic, Cadmium, Selenium Osteoporosises
dc.titleArsenic, cadmium, and selenium exposures and bone mineral density-related endpoints: The HORTEGA studyes
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.doi10.1016/j.freeradbiomed.2020.10.318es
dc.identifier.publicationfirstpage392es
dc.identifier.publicationlastpage400es
dc.identifier.publicationtitleFree Radical Biology and Medicinees
dc.identifier.publicationvolume162es
dc.peerreviewedSIes
dc.description.projectThis work was supported by the Strategic Action for Research in Health sciences [CP12/03080, PI15/00071, PI10/0082, PI13/01848, PI14/00874, PI16/01402 and PI11/00726], CIBER Fisiopatología Obesidad y Nutrición (CIBEROBN) (CIBER-02-08-2009, CB06/03 and CB12/03/30016), the State Agency for Research (PID2019-108973RBC21 and C22), the Valencia Government (GRUPOS 03/101; PROMETEO/ 2009/029 and ACOMP/2013/039), the Castilla-Leon Government (GRS/279/A/08) and European Network of Excellence Ingenious Hypercare (EPSS- 037093) from the European Commission. The Strategic Action for Research in Health sciences, CIBEROBN are initiatives from Carlos III Health Institute Madrid and co-funded with European Funds for Regional Development (FEDER). The State Agency for Research and Carlos III Health Institute belong to the Spanish Ministry of Science and Innovation. MGP received the support of a fellowship from “la Caixa” Foundation (ID 100010434, fellowship code LCF/BQ/IN18/ 11660001).es
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem